MA27724A1 - Utilisation de derives d'isoquinoline aux fins du traitement de cancers et d'etats pathologiques lies a la kinase associee aux membranes (map) - Google Patents

Utilisation de derives d'isoquinoline aux fins du traitement de cancers et d'etats pathologiques lies a la kinase associee aux membranes (map)

Info

Publication number
MA27724A1
MA27724A1 MA28511A MA28511A MA27724A1 MA 27724 A1 MA27724 A1 MA 27724A1 MA 28511 A MA28511 A MA 28511A MA 28511 A MA28511 A MA 28511A MA 27724 A1 MA27724 A1 MA 27724A1
Authority
MA
Morocco
Prior art keywords
treatment
cancer
map
related diseases
membrane associated
Prior art date
Application number
MA28511A
Other languages
English (en)
Inventor
David Bryant Batt
Guido Bold
Sunkyu Kim
Timothy Michael Ramsey
Michael Lioyd Sabio
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA27724A1 publication Critical patent/MA27724A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Cette invention concerne le traitement d'une maladie qui est caractérisée par une voie de transmission de signaux de MAP-kinase aberrante par administration d'un composé de formule (I) dans laquelle les substituants variables sont définis ici, à un patient qui requiert un tel traitement. Le procédé de l'invention est particulièrement utile pour le traitement de cancers qui présentent une RAF-kinase mutée, en particulier un mélanome.
MA28511A 2003-03-11 2005-09-23 Utilisation de derives d'isoquinoline aux fins du traitement de cancers et d'etats pathologiques lies a la kinase associee aux membranes (map) MA27724A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45362403P 2003-03-11 2003-03-11

Publications (1)

Publication Number Publication Date
MA27724A1 true MA27724A1 (fr) 2006-01-02

Family

ID=32990797

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28511A MA27724A1 (fr) 2003-03-11 2005-09-23 Utilisation de derives d'isoquinoline aux fins du traitement de cancers et d'etats pathologiques lies a la kinase associee aux membranes (map)

Country Status (22)

Country Link
EP (1) EP1603566B1 (fr)
JP (1) JP2006519807A (fr)
KR (1) KR20050108383A (fr)
CN (1) CN1758910A (fr)
AT (1) ATE421324T1 (fr)
AU (1) AU2004218914A1 (fr)
BR (1) BRPI0408257A (fr)
CA (1) CA2518530A1 (fr)
DE (1) DE602004019193D1 (fr)
ES (1) ES2318276T3 (fr)
HR (1) HRP20050788A2 (fr)
IS (1) IS8064A (fr)
MA (1) MA27724A1 (fr)
MX (1) MXPA05009687A (fr)
NO (1) NO20054647L (fr)
PL (1) PL1603566T3 (fr)
PT (1) PT1603566E (fr)
RU (1) RU2325159C2 (fr)
TN (1) TNSN05223A1 (fr)
TW (1) TW200501955A (fr)
WO (1) WO2004080464A1 (fr)
ZA (1) ZA200506571B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4939220B2 (ja) 2003-05-15 2012-05-23 アークル インコーポレイテッド ｐ３８の阻害物質としてのイミダゾチアゾール類およびイミダゾオキサゾール誘導体
AR045944A1 (es) * 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
US7829560B2 (en) 2004-07-08 2010-11-09 Arqule, Inc. 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase
WO2006044869A1 (fr) 2004-10-19 2006-04-27 Arqule, Inc. Synthese d'inhibiteurs d'imidazo-oxazole et d'imidazothiazole de la map kinase p38
CN101160131A (zh) * 2005-02-25 2008-04-09 诺瓦提斯公司 Bcr-abl和raf抑制剂的药物组合产品
HRP20110839T1 (hr) * 2005-07-26 2011-12-31 Sanofi Derivati cikloheksaminizokinolona kao inhibitori rho-kinaze
EP2046753A2 (fr) 2006-07-06 2009-04-15 Brystol-Myers Squibb Company Inhibiteurs de type i de la 11-bêta hydroxystéroïde déshydrogénase pyridone/hydroxypyridine
CA2639416C (fr) * 2007-09-11 2019-12-31 F. Hoffmann-La Roche Ag Test de diagnostic pour la susceptibilite aux inhibiteurs de la b-raf kinase
US20110152770A1 (en) 2009-07-30 2011-06-23 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
CN103038364A (zh) 2010-03-09 2013-04-10 达纳－法伯癌症研究所公司 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法
AU2011320565A1 (en) 2010-10-28 2013-05-23 Innocrin Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CN103435430B (zh) * 2013-08-08 2015-02-18 四川大学 一种还原酰胺类化合物的方法
KR102119943B1 (ko) 2018-05-23 2020-06-05 주식회사 포스코 시편배치유닛 및 이를 포함하는 도장밀착성 실험장치
WO2020007807A1 (fr) * 2018-07-02 2020-01-09 Ecole Polytechnique Federale De Lausanne (Epfl) Composés favorisant le lactate et leurs utilisations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
WO2000009495A1 (fr) * 1998-08-11 2000-02-24 Novartis Ag Derives d'isoquinoline possedant une activite d'inhibition de l'angiogenese
DOP2000000070A (es) * 1999-09-28 2002-02-28 Bayer Healthcare Llc Piridinas y piridacinas sustituidas con actividad de inhibición de angiogénesis
WO2001058899A1 (fr) * 2000-02-09 2001-08-16 Novartis Ag Derives de pyridine inhibant l'angiogenese et/ou la tyrosine-kinase du recepteur de vegf
WO2002060392A2 (fr) * 2001-01-31 2002-08-08 Synaptic Pharmaceutical Corporation Utilisation d'antagonistes du recepteur gal3 dans le traitement de la depression et/ou de l'anxiete et composes utiles dans de telles methodes
CA2439263C (fr) * 2001-03-02 2012-10-23 Frank Becker Systeme de dosage a trois hybrides
CA2471314A1 (fr) * 2001-12-21 2003-07-24 Bayer Pharmaceuticals Corporation Polytherapies antiangiogeneses a base de derives de pyridazine ou pyridine
US7220775B2 (en) * 2002-08-07 2007-05-22 H. Lundbeck A/S Compound useful for the treatment of neuropathic pain

Also Published As

Publication number Publication date
NO20054647D0 (no) 2005-10-10
RU2005131168A (ru) 2006-05-27
CA2518530A1 (fr) 2004-09-23
PT1603566E (pt) 2009-04-27
NO20054647L (no) 2005-12-09
ES2318276T3 (es) 2009-05-01
CN1758910A (zh) 2006-04-12
KR20050108383A (ko) 2005-11-16
DE602004019193D1 (de) 2009-03-12
JP2006519807A (ja) 2006-08-31
EP1603566B1 (fr) 2009-01-21
HRP20050788A2 (en) 2006-12-31
RU2325159C2 (ru) 2008-05-27
WO2004080464A1 (fr) 2004-09-23
AU2004218914A1 (en) 2004-09-23
BRPI0408257A (pt) 2006-03-07
EP1603566A1 (fr) 2005-12-14
MXPA05009687A (es) 2005-10-20
PL1603566T3 (pl) 2009-07-31
IS8064A (is) 2005-10-10
ZA200506571B (en) 2006-07-26
ATE421324T1 (de) 2009-02-15
TNSN05223A1 (en) 2007-06-11
TW200501955A (en) 2005-01-16

Similar Documents

Publication Publication Date Title
MA27724A1 (fr) Utilisation de derives d'isoquinoline aux fins du traitement de cancers et d'etats pathologiques lies a la kinase associee aux membranes (map)
TNSN06093A1 (en) 1,4- disubstituted isoquinoline derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases
ATE402929T1 (de) Pyrazinverbindungen als inhibitoren des transforming growth factor (tgf)
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
NO2013008I2 (no) Krizotinib eller et farmasøytisk akseptabelt salt, hydrat eller solvat derav
MXPA05009595A (es) Compuestos 7-amino-isoindolilo y sus usos farmaceuticos.
DE69430747D1 (de) Verbindungen als pde iv und tnf inhibitoren
NO20026242L (no) Syntesemetoder for aplidin og nye antitumorale derivater, metoder for deresfremstilling og anvendelse av disse
ATE311226T1 (de) Die glycin-betain für seine antithrombotische verwendung
EA200500377A1 (ru) Пиразольные производные как ингибиторы трансформирующего фактора роста (tgf)
PT1390371E (pt) Oxazolo- e furopirimidinas e sua utilizacao em medicamentos contra tumores
NO20055741L (no) Nye kjemiske forbindelser
HRP20080057T3 (en) 9,10-alpha,alpha-oh-taxane analogs and methods for production thereof
ATE329909T1 (de) 1,2,3-triazolamid-derivate als cytokininhibitoren
ATE367380T1 (de) Zur behandlung von zns-erkrankungen geeignete piperazinylchinolinderivate
DE60325377D1 (de) Motilidverbindungen
IL166057A0 (en) Urea-substituted and urethane-substituted acylureas methods for the production thereof and their useas medicaments
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
DE60318320D1 (de) Benzimidazolone und ihre verwendung als cytokininhibitoren
CY1106576T1 (el) Υποκατεστημενα παραγωγα 2-πυρρολιδιν-2-υλ-1h-ινδολης για τη θεραπεια ημικρανιας
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen
ATE328883T1 (de) Imidazopyridin-8-one
ATE503476T1 (de) Zusammensetzungen und verfahren zur behandlung von krankheiten, die durch infektion mit yersinia spp ausgelöst sind
DK1406610T3 (da) Anvendelse af substituerede gamma-lactonforbindelser som lægemiddel
CY1111290T1 (el) Παραγωγα 9-αλκυλαμινo-1-νιτρoακριδινης